This blog is a companion piece to an article recently published in our January issue of OBR Green titled “Consumerism in Oncology: How Will it Affect Cancer Care?.” Enjoy the blog and then dig a little deeper by reading the full length OBR Green article here. In healthcare, consumerism is accompanied by an increase in [...]
Quality and Quantity Sometimes in turning over a new calendar year, we don’t take the time to appreciate all that has happened to get us where we are today. We’re more than half way through January and already the highlights of 2011 seem like a distant memory. In catching up with the events of 2011, [...]
San Diego, CA—Data presented at the American Society of Hematology suggest that the antibody conjugate drug, gemtuzumab ozogamicin (Mylotarg; Pfizer)—once approved for use in acute myeloid leukemia (AML) in 2000, and then voluntarily pulled from the market in 2010 due to post-marketing evidence of lack of efficacy, as well as unacceptable toxicity—may have a shot [...]
The Cancer Center Business Summit (http://www.CancerBusinessSummit.com) is a nationally recognized educational resource which deals with oncology/cancer care delivery, oncologist-hospital alignment and integration, and the business, legal, and financial models associated with such initiatives. Each year, in conjunction with its annual conference, the Summit conducts a research survey of current trends affecting the oncology/cancer care sector. [...]
Continuing the tradition of providing you with timely market feedback, OBR and MDoutlook are pleased to share results from MDoutlook’s most recent Quick Poll. This survey was fielded among MDoutlook’s global network of 53,000 cancer physicians to gauge the clinical impact of the recent FDA decision to revoke marketing authorization of bevacizumab (Avastin®) in HER-2 [...]
This blog is a companion piece to an article recently published in our November issue of OBR green titled “Consolidations Come with Concerns as NCI Cooperative Groups Restructure.” Enjoy the blog and then dig a little deeper by reading the OBR green article here. Prior to the recent consolidations, 10 Cooperative Groups had been sharing [...]
With all the breakthroughs and advancements oral oncology drugs are offering to patients with cancer, community oncologists recognize there is a crucial link between the acquisition and management of the oral oncologics and the quality of care delivered to their patients. Through collaborative networking and customized assistance, group purchasing organizations, such as RainTree Oncology Services, are offering practices the opportunity to improve the overall revenue model [...]
November marks Pancreatic Cancer Awareness Month. According to the American Cancer Society, more than 44,000 new cases of pancreatic cancer will be diagnosed in the U.S. and over 37,000 deaths are expected from the disease in 2011. It has the highest mortality rate of all major cancers; 74% of patients die within the first year [...]
STOCKHOLM, SWEDEN –One of the goals of personalized medicine is that genomic sequencing of a patient’s tumor may identify actionable/druggable targets, and therapies aimed at those targets will improve outcomes and possibly cure for cancers. There have been some spectacular successes in personalized medicine – most notably Herceptin for HER2-positive breast cancer and Gleevec for [...]
Though oncologists are well aware of molecular-level testing, the concept may be new for patients. When clinicians discuss treatment plans, patients often focus on little beyond the word “cancer” because their attention is focused on their fear, anxiety, and uncertainty. After diagnosis, patients often call their clinician’s office to rehash the conversation because they don’t [...]
OBR green is our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register to begin receiving OBR green today. View the Most Recent Issue»
